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Abstract: Innovative health technology deployment represents the primary challenge within the
sustainability of public health systems. On one hand, new technologies may potentially improve
access to care and the quality of services. On the other hand, their rapid evolution and broad
implications on existing procedures increase the risk to adopt technologies that are not value for
money. As a consequence, Health Technology Assessment (HTA) is a critical process at each level of
the National Health System. Focusing on the organisational level, this paper explores the current
practices of Hospital-Based HTA (HB-HTA) in terms of management, control and behaviours of
various actors involved. Among several tasks, decision-makers are appointed at managing the
conflict of interest around health technology development, that could pave the way for corruption
or other misleading behaviours. Accordingly, the purpose of the study is proposing a new strategic
framework, named Health Technology Balanced Assessment (HTBA), to foster hospital-based health
technology management aimed to align strategy and actions. The conceptual model is developed
on three perspectives (clinical, economic and organisational) to make the actors involved in the
assessment (clinicians, health professionals, hospital managers and patients) aware of the impact of
new technology on the value chain. Besides supporting the decision-making process, such a tool
represents support for the internal control system as a whole. By promoting structured evaluation,
it increases transparency and accountability of public health organisations. Moreover, in the long run,
the framework proposed will be useful to reach selected United Nations Sustainable Development
Goals (UN SDGs) to enhance the quality of healthcare in the future.
Keywords: hospital-based health technology assessment; corruption; accountability; sustainability;
management accounting; UN SDGs
JEL Classification: M41; H57; I18
1. Introduction
In many countries, health expenditure represents the primary driver of public spending. In fact
the 9% of Gross Domestic Product on average for Organisation for Economic Co-operation and
Development (hereafter OECD) countries is represented by health expenditure. Among all factors of
production, health technologies are commonly considered as the primary driver for burgeoning
cost; indeed, 45% of health expenditure on average across the OECD countries deals with the
funding of investments in health technology [1]. The acquisition of complex and/or innovative
health technologies constitutes the so-called discretional expenditures, since hospital managers have
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a high autonomy in the selection of which innovations have to be adopted. New technologies can
potentially improve population health, access to care and quality of life by providing a more effective
service. Notwithstanding, their successful implementation is strongly influenced by the culture,
structure and impacts on operative processes [2,3]. Therefore, Health Technology Assessment (HTA)
to support decision-making is a critical process within both health policy and the management of health
organisations towards achieving sustainable development goals. The sustainability of health systems
as a whole is strongly determined by the lower levels. Hence, the sustainability of hospital care is felt to
be the most important challenge by the majority of European Union Member States [4]. Due to the large
number of services delivered and the amount of financial resources managed, public hospitals undergo
a high risk of conducting misleading behaviours, which could undermine access to the services and
their quality. In this regard, although a unique definition of corruption has not been provided yet,
there is a shared agreement that “the single greatest obstacle to economic and social development”
is represented by corruption [5,6]. Health facilities are particularly vulnerable to corruption, especially
regarding procurement procedures [7,8]. This is the reason why the organisational dimension of HTA,
named Hospital-Based HTA (HB-HTA) is fundamental in the performance planning and management
of hospitals.
Over the time, many jurisdictions’ reforms have operationally attempted to contain corruption
through the development and/or the improvement of laws regulating corporate governance
mechanisms and internal control tools in the public sector [9]. In fact, since the introduction of
New Public Management (NPM) [10–12] and its evolution to the paradigm of Public Governance
(PG) [13,14], the separation between formulation of policy and administrative action has been
considered the way to improve the efficiency and effectiveness of Public Administration, to contain
opportunistic behaviours and, thus a pre-requisite for a sustainable development. Accordingly, the aim
of the reforms has been to underpin performance management and increase the transparency and
accountability of health organisations. However, in the last ten years, both the evidence collected in
terms of missed performance targets and the financial crisis experienced, demonstrated that the results
achieved were profoundly differed from the expectations.
This paper has a twofold aim: on one hand, it attempts to clarify main attributes of HTA across
different levels of NHS, and to explore potential conflict of interest among actors involved within
health technology deployment; on the other hand, it proposes a new theoretical framework, named the
Health Technology Balanced Assessment (HTBA) to overcome main weakness and to foster a strategic
approach in the management of technology. Hence, this would be a first attempt to answer to the
following research question: is it possible to develop a basic general framework tool for performing
HB_HTA? In particular, the challenge is promoting a more structured, informative and transparent
assessment process for health technologies. The inception of HTBA is retrieved by going back
to the performance management literature, identifying new solutions from it. The framework is
designed on three perspectives of evaluation strictly related to hospital strategic objectives: (i) clinical;
(ii) economic; (iii) organisational. The framework was developed by defining Strategic Objectives for
each perspective of assessment, and, in turns, translating them into Operational Objectives measured
by Key Performance Indicator (KPI). Such an approach tailors a measurement system both to the
technology to be evaluated and to the specific context in which it has to be adopted. Aftermath should
be an accurate definition of goals, embracing interest of all types of stakeholders and considering the
overall strategy of public hospitals.
To address its purposes, the study employed a two-step approach:
1. An exploration of the literature background concerning technology adoption decision-making
and the practices of HTA, with a particular focus on the hospital level;
2. The development of a conceptual framework to support hospital-based technology management,
aligning strategy with operations.
Thus, the remainder of the paper is organized as follows: Section 2 addresses the theme of
HB-HTA, its business function and its connection with the procurement process in the healthcare sector;
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Section 3 disentangles how corruption could take place during HTA; the fourth section proposes the
new framework HTBA; Section 5 critically analyses and discusses findings by underlining the potential
positive impact on misuse of managerial tools, such as the proposed framework. Finally, section
six provides final remarks, forming a bridge between the new framework proposed and UN SDGs in
order to clarify the pursued research pathway better and provide suggestions for further researches.
2. Health Technology Assessment across the National Health System
HTA is known worldwide as the process to systematically evaluate properties, effects and impacts
of health technology from multidisciplinary perspectives [15]. Although it was first conceptualized in
1976 by the Office of Technology Assessment [16], its relevance has been increasing over time due to
the diffusion of expensive medical equipment [17]. HTA affects the three levels—Macro, Meso and
Micro—of the National Health System (NHS), supporting decision-making processes from national
health policies to clinical practice [18]. Therefore, it affects the whole life cycle of health technology.
At the different stages of the life cycle, HTA pursues different scopes, adopts a different approach
in the evaluation and involves various stakeholders. During the phases of technology development,
HTA is strongly policy-oriented in order to assess the eligibility of a new treatment and to define a
reimbursement tariff. These stages involve the Macro level of the NHS, and the assessment of new
technology is usually performed by national HTA agencies. These ones do not have regulative power
but are appointed to produce HTA reports, that collect the best scientific evidence [3] and are not always
mandatory. Recommendations mainly concern clinical and economic aspects. In particular, commonly
the focus is on economic implications, referring to three categories: (a) economic information pertaining
to the social perspective; (b) economic information pertaining to the hospital environment; (c) economic
information pertaining both to social aspects and the hospital environment [19]. Economic information
mostly deals with cost-effectiveness measurement [20] and with cost-benefit analysis [21]. The high
attention given to financial aspects in the early stages of technology development is aimed at increasing
transparency and reducing information asymmetry. Notwithstanding, from an opposite standpoint,
such an evaluation increases the level of uncertainty since not all implications could be identified
in the earlier stages [22]. Several authors underline the importance of involving “social values”
in the assessment, in order to increase transparency, accountability and participation within the
decision-making process [23–25]. Accordingly, an assessment of costs and outcomes from a social
point of view should be added in order to estimate the burden of cost for the patient (and his/her
relatives) and the consequences that health policies have on other industrial sectors. Policy makers,
insurances, industries, clinicians are primarily involved in the evaluative process.
In the majority of countries, HTA deals with the negotiation of the price for pharmaceuticals and
the establishment of those that are covered by public resources. More frequently, it also deals with the
evaluation of medical devices and therapeutic and diagnostic procedures [26]. While in some countries,
HTA refers only to health technologies aimed at treating rare diseases [27]. Significant variation among
HTAs performed in different countries is due to the institutional setting and the independence of HTA
bodies from Health Ministries or insurance agencies.
Once the technology has to be implemented in the clinical practice within a specific environment,
the assessment process is tailored to the organisational structure and supports hospital managers in
defining a technological strategy and planning investment and disinvestment. The adoption process
of new technology in the hospital context follows six main steps: (i) preliminary analysis of the clinical
needs and available treatment options; (ii) assessment of economic and organisational impacts as well
as requisites for tenders; (iii) market analysis and consultation; (iv) choice of procurement procedure;
(v) analysis of different alternatives and final decision; (vi) procurement and logistics [28]. The role of
HTA at the hospital level is to provide a more locally focused technological evaluation, encompassing
both general recommendations and organisational requirements [29–31]. The setting of HTA, thus,
is critical since the context in which it is carried out determines the extent and comprehensiveness
of the assessment [32,33]. HB-HTA, performing by an individual evaluator or a team, could deal
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with clinical practice and/or managerial decisions. In accordance with the matching between the
focus on actions and the organisational complexity, four corporate models for carrying out HB-HTA
duties are identified [34]: (i) ambassador model; (ii) internal committee; (iii) mini-HTA; (iv) HTA unit.
Among these, Mini-HTA and HTA Unit are concerned with managerial decisions. Each factor of the
specific setting and each person involved in the entire decision-making process affect the successful
implementation of new technology in the clinical practice. Although several studies have attempted to
define the best strategy to engage patients in the decision-making process to better align investment to
their needs [35,36], currently only internal stakeholders are involved in HB-HTA activities. Physicians
and surgeons are usually the main instigators of the introduction of new technology into hospitals [37].
Clinicians, health professionals and hospital managers perform the evaluative process, which is
driven by clinical competences trying to respect budget restrictions [29,37–39]. Since drugs are
already assessed by National Medicine Agencies [40], HB-HTA activities concern mainly medical
devices, equipment and/or procedures [39,41–43]. Lafortune et al. argue that the evaluation objective
of HB-HTA has evolved from the capital-intensive technologies to clinical outcomes and delivery
models [44]. Instead, Kosherbayeva et al. state that local assessment should be focused on medical
technology for which there is high demand at the regional level [45].
Figure 1 shows the three levels of HTA, highlighting the type of decision, technology evaluated,
stakeholders involved and dimension assessed at each level.
Figure 1. The Three levels of HTA.
In addition to financial issues, values of stakeholders involved, the external environment
and the organisational setting could either facilitate or hinder technology implementation. Thus,
the technological impact has to be assessed in relation to the health care system, the economy and
society [46]. The assessment of technical and non-technical implications is relevant in particular
within the primary level of care, widely considered the most effective investment in the roadmap
for sustainable healthcare. Technologies aimed to support health promotion and disease prevention,
in fact, foster a co-created provision of health care services between providers and users, that is
transforming traditional conceptions of service planning and delivering. As a consequence, a deeper
understanding of factors that influence behaviours and attitude of both organisation and people are
required. First of all, it is important the understanding of the value of the science for the improvement
of the quality of life [47] and alignment between benefits perceived by patients and those perceived
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by health providers [48]. Besides demographic factors and financial incentives, mutual trust and
communications are critical for the achievement of health objectives [49,50]. In order to improve
patient-provider communication and to enhance co-participation, technology is a leading asset [51].
Then, some cultural factors are relevant to determine successful stakeholder engagement. In particular,
Renedo et al. identified four key elements which highlight the need for a non-hierarchical collaboration
between professional and patients, supported by a constant and iterative process of data collection
and reciprocal training, and a continuous adaption of behaviours toward mutual recognition and
respect [52]. As a consequence, HTA activities are also appointed to manage the conflict of interest
among stakeholders, balancing between the need for the best outcome for patients and the sustainable
business development [53].
3. Opportunistic Behavior in Procurement of Health Technology
The management of the conflict of interest is critical to avoid individual bias and reducing the
room for corruption. As recognised, corruption is a pervasive virus that negatively affects the public
lives of many countries around the world. Many definitions of this phenomenon have been provided
over time [54–56]. One of the most commonly shared definitions is the one provided by Pope [57,58]
according to whom corruption is seen as “the abuse of entrusted power for private gain” [59]. The joint
reading of elements defining the phenomenon (abuse, power, person(s) and private gain deriving from
the abuse) determines that corruption is a consequence of one or more undesirable human actions.
The damages generated by corruption lead not only to a waste of public resources but also undermine
the possibility for sustainable development of countries, increase inequality and determine substantial
well-being losses.
The significant burden of technological innovation within health expenditure has led the
procurement process to be one of the large areas for corruption in the healthcare sector [7,8]. Corrupt
practices and fraud, indeed, affect up to 25% of expenditure on medical and non-medical goods [60].
Improvement in the performance of public procurement might be achieved by tackling, first of all,
problems related to transparency, procurement irregularities and the number of tenders to purchase
equipment [4].
As stressed in the literature, the so-called institutional corruption figures fall into two types:
collective and individual [61]. Focusing on the local level and transposing to the health sector the
useful reasoning of Beeri and Navot [62] about local government political corruption, potential structural
malfunctions could be observed at the NHS-hospital or Region-hospital level (central-local), among
hospitals in competition (intra-local) or, even, among hospital managers and/or doctors in the hospital
itself (local-local). In respect of procurement, opportunistic behaviours are strongly encouraged by
unstoppable interactions between public and private sectors, which involve various stakeholders with
different perspectives concerning the value added by health technologies [63]. Multinational corporations
require adequate rewards to increase profit and to fund further researches. Public hospitals are appointed
to guarantee the provision of health care, balancing the need for cost constraints with a good quality of
services to create even more value for patients. Payers seek new technologies whose additional benefits
justify the cost. Patients and health practitioners assess the value of health technologies in relation to
benefits for the individual, irrespective of costs. Due to these different approaches among actors towards
value creation, corruption represents the result of power abuses from actors, who illegally overcome
rules, giving or promising different types of rewards to other actors, who join in with the opportunistic
behaviours. Moreover, healthcare professionals do not always fully understand what is corruption
and its impact on their work. At the same time, regulators and anti-corruption specialists often do not
understand both the complexity and peculiarity of the healthcare system.
Healthcare technologies (and services derived from them) adoption and implementation are
the result of a complex mosaic in which the behaviors of actors are predominant in determining
final choices. The interactions among actors towards successful technology development has been
explored in accordance with other perspectives, such as the patients’ willingness to pay for several
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health services as a function of the distribution of information among different actors belonging to
the health value chain [50]. As mentioned above, HTA involves different stakeholders throughout
its steps, and not all of them are involved in all levels. Analysing the dynamics of HTA and how
the decision-making process is carried out at each level of the NHS, therefore, is critical to identify
trigger events that could create room for corruption from and among different actors. At the Macro
level, the evaluative process concerns mainly political decisions; thus, main risks are represented by
collusive agreements among politicians, civil servants and big corporations. Although it is difficult to
understand how decisions taken at the Macro level could be detrimental to hospitals or healthcare
authorities individually, corruption has a broad effect on healthcare [7]. Corruption from the highest
levels, in fact, will trickle down to affect the health care received by patients at local healthcare
facilities. If the NHS decides to adopt one technology over another, which has a lower efficacy,
patients will be damaged as well as the reputation of the single healthcare “provider”. Distorted
policies and improper priority setting could lead to wasted resources and to a decrease in the access to
treatments. Different types of criticism could be observed moving to the Meso level, where hospital
managers are involved in decisions that regard purchasing and employment of health technologies into
hospitals. Bargaining processes between healthcare technology providers and hospitals take place in
different ways: from a generic price and volume technologies negotiations to the choice of which units,
departments, even medical equips can adopt and use technologies. In this setting, corruption trigger
events are represented by the possibility to alter a fair economic price, clinical efficacy, maintenance
needs, usage of technologies and so on for pursuing private gains. Despite the acknowledged lack of
guidelines for well-performing HT-HBA, the process must be tailored to the specific hospital context
where it takes place [28]. Due to a more operations-oriented approach, clinicians have a leading part
both in the selection and implementation of new technologies. In this scenario, the role of the law
in regulating hospital management discretion and power, and the existence and effectiveness of the
internal control system and governance rules, determine the creation of a favourable/unfavourable
environment for corruption. The higher the ineffective managerial structures and control mechanisms,
the higher the possibility of observing corruption [8].
Figure 2 summarises actors involved during the different stages of HTA and interactions
among them.
Figure 2. Actors and dynamics involved in the HTA process.
Evidence of the AdHopHTA Project [28,64] emphasised how HTA phases are similar among
hospitals, while comparators to be used, perspectives to be assessed, stakeholders to be engaged
and tools to be adopted varied considerably. Several studies were carried out to explore if some
decision-making tools could be applied to improve HB-HTA activities [29,31,42,46,65–67]; however,
a scientific literature about suitable methodologies does not exist yet. Recommendations produced by
HB-HTA are usually mandatory, even if decision-makers are more compliant with clinicians’ requests
for new technology [64].
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Aftermaths of these approaches are investment decisions supported by inadequate or insufficient
information that creates a large amount of room for pursuing opportunistic behaviours. In particular,
involving only medical, safety, technical and financial issues in the assessment of new technology
does not consider the relevance of organisational features towards their successful implementation.
These aspects, which are already evaluated both to obtain CE marking and to introduce new technology
into the NHS, have to be contextualised within a specific organisational environment.
Trying to fill some of the gaps in the current practices of HB-HTA and to foster a more structured
and accountable procurement and adoption of health technologies, the next paragraph proposes a new
framework: Health Technology Balanced Assessment (HTBA).
4. “Health Technology Balanced Assessment” Framework
For selecting technologies that are value for money for the organisation, the HB-HTA has to be
consistent with the specific environment and oriented towards the daily management of the technology.
It should consider vision, mission, critical success factors, strategies, plans and organisational structure
to support better decision-making processes. Moreover, it should be able to involve all relevant
perspectives and to orient the priorities of each actor towards sustainability of the system as a
whole [68]. So far, the sole framework to support HTA activities is the HTA Core Model [69] proposed
by the European Network for Health Technology Assessment (EUnetHTA). It covers nine domains:
(i) health problem and current use of technology; (ii) description and technical characteristics; (iii) safety;
(iv) clinical effectiveness; (v) costs and economic evaluation; (vi) ethical analysis; (vii) organisational
aspects; (viii) patient and social aspects; (ix) legal aspects. The aim of the Model is providing a
methodological approach to defining research questions within several areas. Notwithstanding, as it
stands, it does not offer a tool to assess the different items.
This may be the reason why experiences of empirical application are still scarce. Moreover, due to
the absence of a strategical dimension [70], it is more useful for performing HTA at early stages of new
technology development.
Embracing a strategic approach in tackling HB-HTA is a serious issue in the digital era [71,72].
Technology development, in fact, can potentially improve the quality of services provided as well
as the quality of life of patients. At the same time, it is transforming ways by which health care is
delivered, reflected in cost, management, operations and behaviours. Therefore, sustainability of
health systems is strictly related to the management of the adoption and implementation of the results
of innovative technologies [73]. The sustainable development could be achieved through suitable
governance models and effective practices. Accordingly, investment decisions on new technologies
should be taken by balancing both the need for cost containment and the need for innovation.
As stressed previously, three main assessment perspectives are in the literature around HB-HTA:
(i) clinical; (ii) economic; (iii) organisational. Each assessment perspective provides essential
information in order to better identify all implications for the technology uptake. Efficacy and
effectiveness are the significant concerns for clinicians and hospital managers who seek new modalities
to improve the treatment of disease and who are often determined to become forerunners in their
specific medical field [74]. Patients, instead, are engaged to find those treatments that could improve
their health status and enhance the quality of their life. Reimbursement mechanisms and budget
rules represent financial restrictions that affect decision-making and sometimes could lead to the
adoption of technology that is not clinically justified [75]. Hospital capacity, specialisation and internal
arrangements are critical to the successful implementation of clinical practice [64].
Performance management theories, aimed at fostering a holistic approach in the understanding
and management of the value chain [76–78], could represent the basis for the development of a
new management system to support HB-HTA. Performance management systems, such as the most
well-known Balanced Scorecard [79], Performance Prism [80], Tableau de Bord [81] and others foster
evaluation approaches supported by tools for integrating traditional accounting indicators with
additional financial and non-financial measures. This way, financial assessment, through specific
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cause-effect relationships, is combined with other relevant dimensions, which may ensure the overall
sustainability of investments in new technology. Similar tools contribute to the translation of strategies
into actions. Notwithstanding, it is crucial to summarise the various measures and assign different
priorities to support the decision to be taken. Accordingly, management systems could be aided by
Multi-criteria Decision Analysis (MCDA) methods, which allows decision-makers to manage better the
plethora of issues that have to be considered and to determine a solution transparently. These methods
analyse and evaluate different alternatives, monitoring their impact on the various actors [82].
Summing up the importance of actors, users and their related needs, the provision of a general
framework “in” and “for” hospital, named the Health Technology Balanced Assessment (HTBA),
might be outlined to compare different alternatives for achieving desired results. Accordingly,
the primary objective of the HTBA framework is to improve the employment of public financial
resources in technological investments that have a higher value for money for the organisation.
The decision-making process complies with several phases aimed at: defining various alternatives
and formulating different scenarios; assessing options by adopting several criteria, usually measured
by indicators; selecting the best choice among those taken into consideration. The implementation of
the HTBA framework to support decision-makers requires that some specific steps must be followed
in order to increase the awareness of decision-makers and the transparency and accountability of the
decision-making process.
STEP 1. The first step is the definition of relationships between perspectives of assessment and the
strategic objectives of the healthcare organisation related to investments in health technology. This stage
represents the basis for designing a technology strategy consistent with both the overall strategy and
the structure. Regarding the three above-defined perspectives, health technology investments should
first support reaching general strategic goals by:
1. improving clinical effectiveness and increasing patients’ satisfaction and engagement from the
clinical perspective;
2. optimising employment of financial resources, maintaining (or improving) the same level of
access and quality of health services from the economic perspective;
3. improving the efficacy and effectiveness of internal processes and increasing staff satisfaction
from the organisational perspective.
Figure 3 shows an example of the general HTBA framework. Starting from the HTBA mission
(the grey circle), 3 couples of strategic objectives, interconnected each other are assigned to the three
perspectives of appraisal. Strategic objectives could differ among hospitals; the proposed spider-graph
has only the aim to shape the sorting logic of a generic HB-HTA following a balanced approach.
Figure 3. HTBA generic evaluation framework as a result of a strategic phase (1st HTBA step).
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STEP 2. The second step for the HTBA implementation concerns the cascading of strategic
objectives into operational objectives, and the resulting definition of KPIs and related targets.
This phase is critical to effectively make HTBA a support for an improved assessment of health
technologies. Furthermore, defining the cause-effect relationship among strategic and operational
objectives promotes the understanding of how each aspect related to the technology contributes to the
attainment of desired outcomes. Referring to the three perspectives:
1. the clinical perspective deals with medical and technical issues in order to assess if a technology
represents an effective treatment of a specific disease and how it works. Moreover, it is aimed at
capturing patients’ needs and implications, referring not only to their health status but also to
their satisfaction and physiological sphere;
2. the economic perspective involves all financial issues, presented by the investment effort,
cost savings or potential additional revenues;
3. the organisational perspective assesses which implications on current arrangements and
procedures are by the adoption of new technology. In particular, it is performed to understand if
(and which) organisational changes, in terms of roles and competencies, and training activities
are required for a successful implementation.
Once operational objectives are identified, a set of KPIs has to be defined to develop a control
system, which could monitor the accomplishment of performance targets within each perspective.
Indicators are the expressions of criteria adopted to summarise the performance of the system under
strategic alternatives to orient behaviours of the organisation. Benchmarks represented by targeted
results correspond to thresholds useful for guiding the decision-making process.
Figure 4 shows the logic cascading of assessment perspective into the performance measurement
system of the HTBA theoretical framework. Each perspective of technology evaluation, starting from
the recognition of the specific strategic objectives, could be conveyed into operational objectives, which,
in turn, are measurable by a system of KPIs. This theoretical approach takes into account both the
performance achievable and its comparison with the expected target. Accordingly, this fits with general
management necessities to verity if investment decisions are aligned with healthcare general mission
and strategic orientation.
STEP 3. The last step of the HTBA development deals with the identification of a tool to gather
and summarise the results of the assessment process. This could be represented by a dashboard that
provides results of each KPI in the form of a video screen to monitor performance towards the desired
targets. Such a system could clearly explain the consequences expected due to the introduction of
new technology from different perspectives. The adoption of intuitive dashboards could enhance the
readiness of information for all users, fostering engagement with and accountability of the HB-HTA.
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Figure 4. From strategy to operations. operational objectives and KPIs identification phase (2nd HTBA step).
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Figure 5 draws out an example of a spider graph, as a possible intuitive dashboard. The graph
shows the contribution to the business performance achieved through the technology under assessment.
The dashboard allows users to capture the achieved targets for each indicator linked to both operational
and strategic objectives and, in turn, with the three perspectives forming the overall assessment
process. Thresholds for each indicator should be established before the evaluative process. Later,
by performing variance analysis, results achieved could be helpful to orientate the decision-making
process. The comparison may be useful for formulating appreciations, going on with further analysis,
or modifying indicators. Non-management skilled stakeholders (e.g., clinicians, patients, hospital
manager with a more law focused education), in fact, are confident with customer satisfaction survey
and/or questionnaire based on indicators and thresholds (for an application of the logic in the
Vietnamese health sector see Vuong [83]).
Figure 5. Formalizing and monitoring performance achievements: the dashboard control. (3rd step of HTBA).
The use of the HTBA framework allows decision makers to have a complete set of information
about the widespread impact of the employment of new technology within a Hospital Institution.
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In this way, HTBA becomes the operational tool for the fulfilment of the HB-HTA assignments;
thus, it allows clinical managers to:
• Collect the information needed for the HT evaluation based on different qualitative and
quantitative scales;
• Aggregate this information set based on specific assessment requirements;
• Analyse the results gathered by the assessment process;
• Summarise the results of the assessment in order to make them comparable with the
targeted expectations.
Among all potential benefits, this pathway, more structured and formalized, could allow
decision-makers to evaluate the coherence of investment choices with the general strategic orientation
of the organisation to which it is applied.
5. A Performance-Driven Hospital-Based HTA for Sustainable Development
In order to tackle the debate around the sustainability in healthcare, several issues have
to be disentangled. The first critical one concerns health system governance and, in particular,
the centralisation/decentralisation of the decision-making process across the NHS. This issue is
particularly significant within the procurement of health technology. Among all implications, it is
important to define tasks appointed to technologies evaluated and stakeholders involved for each level
of HTA. Up to now, there is still a scarce culture around HTA. In particular, it has not been understood
what HB-HTA is, how it differs from HTA performed by national or regional agencies and why it may
be relevant to the management of hospitals. As a consequence, hospital activities of HTA are largely
neglected in favour of the HTAs conducted at the Macro level of NHS and decisions taken by single
practitioners (at the Micro level). Besides, its role is restricted to the assessment phase in almost all
cases. Therefore, rarely are HB-HTA activities performed by adopting a holistic approach and enlarged
to other phases within health technology management and hospital management as a whole [64].
Notwithstanding, the evaluation of equipment, medical devices and procedures—usually performed
at the Meso-level of NHS—requires a “managerial-rational” approach. Such an approach needs to
be supported by the involvement of different competencies and, thus, by a variety of stakeholders.
Healthcare professionals (both physicians and nurses) have to evaluate which alternative is easier
to use and will give the best outcome for patients. Clinical engineers are appointed evaluators of
technical implications and all issues regarding installation, maintenance and repair. Administrators
and managers refer to economic aspects and organisational requirements, in terms of staffing and
structural needs [84]. Stemming from distortions and conflicts of interests in the public procurement
procedures, Directive 2014/24/EU regulated the use of different sorts of information ahead of cost [85].
This statement is forehanded in the perspective of sustainable development, strongly influenced by
social, environmental and cultural dimensions besides economic aspects [86]. Therefore, different
perspectives have to be reconciled to guarantee universal access to innovative and costly technologies
in the future [63].
Adopting this standpoint, HB-HTA may have a broader definition, representing a process
for improving strategic performance planning and the management of health facilities as a whole.
Practices of HB-HTA are strongly influenced by internal and external factors that shape the design
of organisational structural variables [64]. As illustrated by Drummond et al., HTA for supporting
resource allocations has to comply with 15 principles [87]. The principles concern the structure of
HTA of the assessment programme, methods and perspectives adopted, processes followed, and the
degree of influence on the decision-making process. In order to fill gaps in the current practices of
HB-HTA, the above-explained HTBA Framework could represent a tool to measure the impacts of
each solution from financial and non-financial perspectives. The involvement of multidisciplinary
dimensions is critical for operating in the lens of sustainability [88]. Moreover, the HTBA promotes a
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higher alignment between the selection of technologies to be adopted and the specific environment, by
monitoring:
• the consistency with overall strategy;
• the cause-effect relationship among different strategic and operating objectives;
• impacts on internal processes;
• the overall sustainability of hospitals taking into consideration the external environment,
social needs and patients’ expectations.
Within each perspective, HTBA allows users to easily compare the results achieved both
to comparators available in the clinical practice [28] and to the level of performance targeted.
The understanding of implications related to innovation implementation contributes to making various
stakeholders more aware of critical factors in the value chain. In addition to higher engagement,
this encourages performance-driven mentality in healthcare, which has not still been developed as well
as for NPM and PG’s purposes [89]. Such an approach, on the one hand, increases the assumption of
responsibility for management and decision-makers; on the other, it improves procurement policies and
processes, the quality of technologies adopted and, as the last (but not the least) result, the well-being of
citizens. A structured process of HB-HTA as well represents support in the management of the conflict
of interest, which often plague the sustainability of health systems and pave the way for corruption.
Due to decentralisation that usually characterises the decision-making process in the public sector,
the issue of corruption has to be also explored through the agency problem lenses [90]. However,
this approach for public administration is not straightforward since there is not a direct link between
ownership and control as happens in private firms [91,92]. The owners of public hospitals, indeed,
are citizens who cannot nominate or oversight managers directly. This mechanism implies low control
and, in the end, leaves higher power and discretion in making choices in the hands of managers [93].
In addition, most of the time, when managers’ misconducts arise, a higher lag in comparison with the
private sector is observed in punishing or sacking them.
That is why the acknowledged need for an ex-ante better design of governance mechanisms,
internal system controls and performance management tools as a whole, is felt even more in the
public sector. Further, in organisations that are social value-oriented, such as those in the health sector,
performance measurement activities are more difficult as the monetary unit loses a considerable part
of its efficacy in evaluating results. As contended in the literature [94–97], the best way to minimise
this loss in capturing the value created is represented by striving efforts towards better accountability.
However, if higher accountability in the past was required for better figuring out performance achieved,
today it is essential for preventing opportunistic behaviours, and avoiding information losses [98].
It is clear that for one that gains from misconducts, there is another one (or more) that incurs a
loss. Referring this reasoning to public hospitals can easily allow us to conclude that the losers usually
are represented by patients, and related damages could be catastrophic. Internalizing the cost of (or the
loss generated by) misconducts, even corruption [99] is, therefore, the result of two main components:
governance mechanisms and internal control systems adopted.
Implications of corruption in the procurement of health technology are mainly represented by
the acquisition of low-quality and ineffective products, that are not aligned with health needs [7].
Misleading behaviours sometimes lead to the introduction of innovative treatments whose high
cost could increase inequalities. Inability and/or willingness to pay for medical services, indeed,
is commonly considered as the primary barrier to access to care from patients’ standpoint [4].
Accordingly, the proposed framework would attempt to involve the different perspectives
of various stakeholders and all relevant issues to identify the implications of new technology on
organisational context. Among all potential benefits, HTBA should be able to increase awareness in
the decision-making process, boosting public hospitals’ accountability and transparency [100,101].
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6. Final Remarks
In the analysis of the value created by healthcare organisations, the social perspective seems to
be the most important. Accordingly, we may interpret the concept of value-added in terms of social
value-added. Features such as economic productivity, diversification, upgrading and innovation of
technologies are the essence within the process of value creation. These aspects are also the basis for
planning hospital capacities by adopting a comprehensive approach.
After the research pathway aimed at depicting the existing weaknesses of HB-HTA practices and
then at proposing a new model for overcoming these weaknesses, we undertaken a holistic reading of
UN SDGs. The aim was to prompt reflections around the usefulness of the model in achieving several
of them.
First of all, the focus on the local level is strictly related to the belief that increasing the
sustainability of hospital care is critical for improving the sustainability of the health system as
a whole. Issues such as universal health coverage, access to quality essential care services, safety and
effectiveness could be achieved only if hospitals move towards a more sustainable technological
development. Assessing relevant issues of the three perspectives (clinical, organisational and
economical) of the proposed model is critical for the achievement of the afore-mentioned objectives
(UN SDG 3). As seen, previous studies dealt, on the one hand, with the need for tailored HB-HTA
procedures in the light of the peculiarities of organisations; on the other, they provided evidence of
successful experiences of HB-HTA. However, there are no studies, apart from this attempt, privileging
the managerial and control perspectives for improving the procurement processes of public hospitals
(UN SDG 12) taking into account different interests involved in the process.
Due to diversities among jurisdictions and realities, many are the trigger events where
maladministration or even corruption could affect procurement procedures. To promote, sustainable
public procurement practices, interests of all stakeholders involved and, in the end, the interest owned
by patients have to be balanced. Better accountability and transparency together with less corruption
within public hospitals’ technologies acquisition processes could be pursued only through a general
framework when performing HT evaluation (UN SDG 16). A structured Meso level of HTA could
countervail between political pressures coming from the Macro level and personal abuses of entrusted
power coming from the Micro level.
An advanced, sustainable management accounting tool for promoting better decisions could be
significant towards the achievement of higher innovation, productivity and social value (UN SDG 8).
Otherwise, by referring only to the right intuitions from physicians and/or managers we might win
some battles but never the war.
In conclusion, in accordance with Ball and Bebbington [88], this paper has tried to answer
how public health organisations could effectively disentangle their responsibilities for sustainable
development performance. Moreover, passing through accounting techniques useful to guide public
sector organisations’ actions, and to what accounts may describe their performance, we tried to build
the bases for better accountability.
Further researches might address the application of the proposed model in different public
healthcare organisations and across jurisdictions to test its rationale and effectiveness and to improve
it continuously. For academics, we encourage contributions aimed at enriching the inner logic of the
model. In this respect, contributions from hospital managers and physicians would also be desirable.
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